FATE – Fate Therapeutics, Inc.
FATE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
9.68
Margin Of Safety %
Put/Call OI Ratio
0.15
EPS Next Q Diff
EPS Last/This Y
0.13
EPS This/Next Y
0.1
Price
2.05
Target Price
5.41
Analyst Recom
1.91
Performance Q
76.07
Upside
-1,264.1%
Beta
2.58
Ticker: FATE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-18 | FATE | 1.74 | 0.17 | 0.01 | 4150 |
| 2026-05-19 | FATE | 1.88 | 0.14 | 0.03 | 5015 |
| 2026-05-20 | FATE | 1.835 | 0.12 | 0.00 | 5949 |
| 2026-05-21 | FATE | 2.11 | 0.11 | 1.05 | 6134 |
| 2026-05-22 | FATE | 2.24 | 0.14 | 0.11 | 6637 |
| 2026-05-26 | FATE | 2.14 | 0.15 | 0.03 | 6828 |
| 2026-05-27 | FATE | 2.36 | 0.15 | 0.09 | 6777 |
| 2026-05-28 | FATE | 2.62 | 0.14 | 0.06 | 6849 |
| 2026-05-29 | FATE | 2.84 | 0.14 | 0.29 | 7236 |
| 2026-06-02 | FATE | 2.56 | 0.20 | 0.00 | 5932 |
| 2026-06-03 | FATE | 2.2 | 0.19 | 0.07 | 6197 |
| 2026-06-04 | FATE | 2.2 | 0.19 | 0.03 | 6336 |
| 2026-06-05 | FATE | 1.98 | 0.16 | 0.15 | 7381 |
| 2026-06-08 | FATE | 1.9 | 0.15 | 0.01 | 7620 |
| 2026-06-09 | FATE | 1.9 | 0.15 | 0.40 | 7739 |
| 2026-06-10 | FATE | 1.875 | 0.15 | 0.00 | 7783 |
| 2026-06-11 | FATE | 1.965 | 0.15 | 0.04 | 7799 |
| 2026-06-12 | FATE | 2.055 | 0.15 | 0.02 | 7822 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-18 | FATE | 1.74 | 14.1 | - | -1.13 |
| 2026-05-19 | FATE | 1.89 | 14.1 | - | -1.13 |
| 2026-05-20 | FATE | 1.83 | 11.0 | - | -0.99 |
| 2026-05-21 | FATE | 2.11 | 11.0 | - | -0.99 |
| 2026-05-22 | FATE | 2.24 | 10.9 | - | -1.00 |
| 2026-05-26 | FATE | 2.14 | 11.2 | - | -1.04 |
| 2026-05-27 | FATE | 2.36 | 11.2 | - | -1.04 |
| 2026-05-28 | FATE | 2.62 | 11.2 | - | -1.04 |
| 2026-05-29 | FATE | 2.84 | 11.2 | - | -1.04 |
| 2026-06-01 | FATE | 2.73 | 11.2 | - | -1.04 |
| 2026-06-02 | FATE | 2.56 | 11.2 | - | -1.04 |
| 2026-06-03 | FATE | 2.19 | 11.2 | - | -1.04 |
| 2026-06-04 | FATE | 2.20 | 11.2 | - | -1.04 |
| 2026-06-05 | FATE | 1.97 | 11.2 | - | -1.04 |
| 2026-06-08 | FATE | 1.90 | 11.2 | - | -1.04 |
| 2026-06-09 | FATE | 1.89 | 11.2 | - | -1.04 |
| 2026-06-10 | FATE | 1.87 | 11.2 | - | -1.04 |
| 2026-06-11 | FATE | 1.97 | 11.2 | - | -1.04 |
| 2026-06-12 | FATE | 2.05 | 10.7 | - | -1.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-18 | FATE | -0.29 | 10.19 | 9.23 |
| 2026-05-19 | FATE | -0.29 | 10.19 | 9.23 |
| 2026-05-20 | FATE | -0.29 | 10.19 | 9.23 |
| 2026-05-21 | FATE | -1.26 | 10.19 | 9.23 |
| 2026-05-22 | FATE | -1.26 | 10.19 | 9.23 |
| 2026-05-26 | FATE | -1.26 | 11.91 | 9.28 |
| 2026-05-27 | FATE | -1.15 | 11.91 | 9.28 |
| 2026-05-28 | FATE | -1.15 | 11.91 | 8.80 |
| 2026-05-29 | FATE | -1.15 | 11.91 | 8.80 |
| 2026-06-02 | FATE | -1.15 | 11.29 | 8.80 |
| 2026-06-03 | FATE | -1.15 | 11.29 | 8.80 |
| 2026-06-04 | FATE | -1.15 | 11.29 | 8.80 |
| 2026-06-05 | FATE | -1.15 | 11.29 | 8.80 |
| 2026-06-08 | FATE | -1.15 | 11.30 | 8.80 |
| 2026-06-09 | FATE | -1.15 | 11.30 | 8.80 |
| 2026-06-10 | FATE | -1.15 | 11.30 | 9.68 |
| 2026-06-11 | FATE | -1.15 | 11.30 | 9.68 |
| 2026-06-12 | FATE | -1.16 | 11.30 | 9.68 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.26
Avg. EPS Est. Current Quarter
-0.26
Avg. EPS Est. Next Quarter
-0.26
Insider Transactions
-1.16
Institutional Transactions
11.3
Beta
2.58
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
12
Growth Score
31
Sentiment Score
52
Actual DrawDown %
97.9
Max Drawdown 5-Year %
-99.3
Target Price
5.41
P/E
Forward P/E
PEG
P/S
37.99
P/B
1.33
P/Free Cash Flow
EPS
-1.09
Average EPS Est. Cur. Y
-1.02
EPS Next Y. (Est.)
-0.92
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2056.79
Relative Volume
1.67
Return on Equity vs Sector %
-99.9
Return on Equity vs Industry %
-83.5
EPS 1 7Days Diff
EPS 1 30Days Diff
-1.02
EBIT Estimation
◆
FATE
Healthcare
$2.06
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
50.4
Range 1M
34.1%
Sup Dist
9.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
6.4%
EPS NY
9.7%
52W%
56.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+162.6% upside
Upside
+162.6%
Quality
12
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 161
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
FATE
Latest News
—
Caricamento notizie per FATE…
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading